Navigation Links
Michael D. Taylor, Ph.D., Joins Cequent Pharmaceuticals' Board of Directors
Date:5/5/2008

CAMBRIDGE, Mass., May 5 /PRNewswire/ -- Cequent Pharmaceuticals, a pioneer in the development of novel products to deliver RNAi-based treatments to prevent and treat human disease, announced that Michael D. Taylor, Ph.D., has joined the company's board of directors. Dr. Taylor is president and chief executive officer of Ensemble Discovery Corporation, a Cambridge, Massachusetts-based biotechnology company developing novel classes of therapeutics and bioassays using its proprietary DNA Programmed Chemistry(TM) (DPC(TM)) platform.

"Mike is a terrific addition to our board," said Cequent President and CEO, Peter Parker. "With more than 20 years in the pharmaceutical industry, his extensive experience ranges from drug discovery -- leading early and late-stage development projects across multiple therapeutic areas, including Lipitor(R) and Neurontin(R) -- to licensing, business development, and managing R&D alliances with pharmaceutical and biotech partners. His counsel and strong industry relationships will be valuable assets to Cequent as we continue to move our clinical candidates from pre-clinical development toward a successful IND submission with the FDA."

Dr. Taylor joined Ensemble Discovery Corporation in July of 2007. Previously, he was senior vice president for Pfizer's Global R&D division. In addition to his R&D experience, he is active in investor development, government affairs, and public policy affecting the pharmaceutical industry. Until 2003, he was adjunct professor of medicinal chemistry at the College of Pharmacy at the University of Michigan, where he was active in teaching medicinal chemistry and biopharmaceutics. Dr. Taylor has authored or coauthored 65 manuscripts and published abstracts, and holds six patents.

Dr. Taylor has a doctorate in medicinal chemistry from the State University of New York at Buffalo and was awarded an NIH postdoctoral fellowship in natural products synthesis and structure elucidation at the University of Pennsylvania.

About Cequent Pharmaceuticals, Inc.

An early-stage biopharmaceutical company, Cequent is pioneering the development of novel therapeutics to prevent and treat a wide range of human diseases -- from inflammatory diseases to cancer -- based on the company's proprietary technology, TransKingdom RNA interference (tkRNAi(TM)). Cequent's first products, now in pre-clinical development, are drug candidates targeting colon-cancer prevention and inflammatory bowel disease. The company designed its powerful tkRNAi technology to deactivate specific disease-causing genes safely and effectively, using non-pathogenic bacteria as an engine to produce and deliver RNAi directly into cells. It is based on ground-breaking scientific research originating at the Beth Israel Deaconess Medical Center/Harvard Medical School. A privately held company based in Cambridge, Massachusetts, Cequent was established in 2006. For more information, visit http://www.cequentpharma.com.


'/>"/>
SOURCE Cequent Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Michael Troullis Appointed Chief Financial Officer of Quintiles Transnational Corp.
2. Emisphere Technologies, Inc. Appoints Michael R. Garone chief financial officer
3. Genstar Names Michael Hurt to Its Strategic Advisory Board
4. Keryx Biopharmaceuticals, Inc. Announces Appointment of Michael P. Tarnok to Board of Directors
5. MacroChem Announces Michael Zasloff, M.D., Ph.D. Joins Companys Scientific Advisory Board
6. Pharmasset Appoints Michael Rogers as Chief Development Officer
7. The Michael J. Fox Foundation Awards $2 Million to Shed Light on Role of LRRK2 and Alpha-Synuclein Genes in Parkinsons Disease
8. ImmunoVaccine Technologies appoints the Honourable Michael Kirby as Chair
9. Michael J. Simms Joins Alexza Pharmaceuticals as Senior Vice President, Operations and Manufacturing
10. Dr Michael Rosenblatt Appointed Non-Executive Director at Shire
11. DermTech Appoints BioStatistical Pioneer, John Quackenbush, Ph.D., as a Member of the Companys Scientific Advisory Board
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/3/2016)... NEW BRUNSWICK, N.J. , Feb. 3, 2016 ... 30 grants totaling more than $1 million for ... who are working on health-related research that demonstrates ... , this round of funding for the New ... available for faculty members at these educational institutions— ...
(Date:2/3/2016)... ... February 03, 2016 , ... ... and Unix visualization solutions today announced the addition of a powerful “Session Preview” ... to see the current state of the remote Linux desktop or other applications ...
(Date:2/3/2016)... 2016  Today, Symphony Technology Group (STG) announced the ... leading provider of primary research and analytics-based insight for ... , a global information and technology services company serving ... will be integrated into IMS Health to form a ... capabilities. ...
(Date:2/3/2016)... LATHAM, NEW YORK. (PRWEB) , ... February 03, ... ... and manufacturer of silicon (Si) and InGaAs chips and wafers, and InP epi ... detectors ranging from silicon detectors–including photodiodes, photo transistors, and Avalanche photodiodes–to Si ...
Breaking Biology Technology:
(Date:2/1/2016)... , Feb. 1, 2016  Today, the first day ... announced plans to develop a first of its kind ... of IBM Watson. In the first application of ... (NYSE: IBM ), and Welltok will create a ... assessments with cognitive analytics, delivered on Welltok,s health optimization ...
(Date:1/27/2016)... Ohio , Jan. 27, 2016  Rite Track, ... based in West Chester, Ohio ... award winning service staff, based in Austin, ... capacity and ability to provide modifications, installations and technical ... Dovalina , CEO of PLUS, commented, "PLUS has provided ...
(Date:1/22/2016)... , January 22, 2016 ... the addition of the  "Global Behavioral ... offering. --> http://www.researchandmarkets.com/research/4lmf2s/global_behavioral ) ... "Global Behavioral Biometric Market 2016-2020"  report ... Research and Markets ( http://www.researchandmarkets.com/research/4lmf2s/global_behavioral ) has ...
Breaking Biology News(10 mins):